This Week in CRC Research — July 12, 2026
Weekly colorectal cancer research intelligence
braf
A collection of 30 issues
Encorafenib and cetuximab re-challenge combined with nivolumab in BRAF-mutated colorectal cancer
Skip to content
The CRC Digest
▸ TREATMENT
Encorafenib and cetuximab re-challenge combined with nivolumab in BRAF-mutated colorectal cancer — Clinical Colorectal Cancer
A case report from the AGMT mCRC Registry documented successful encorafenib and cetuximab re-challenge combined with nivolumab in BRAF V600E mutated, mismatch-repair-proficient metastatic colorectal cancer.
If you have BRAF
KRAS, NRAS, and BRAF mutation patterns in Chile
Skip to content
The CRC Digest
KRAS, NRAS, and BRAF mutation patterns in Chile
Real-world data from 999 Chilean patients characterized the frequency and sex-specific distribution of KRAS, NRAS, and BRAF mutations. (Journal of Gastrointestinal Oncology)
This content is informational only and does not constitute medical advice.
Always consult your
RAS and BRAF status in MSI-H/dMMR metastatic CRC
Skip to content
The CRC Digest
RAS and BRAF status in MSI-H/dMMR metastatic CRC
New guidance on the role of RAS and BRAF mutations in MSI-high and dMMR metastatic colorectal cancer. (Oncodaily)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care
CRC Research Update — July 06, 2026
Today's colorectal cancer research highlights
BREAKWATER explores molecular markers in BRAF V600E disease
Skip to content
The CRC Digest
BREAKWATER explores molecular markers in BRAF V600E disease
Phase III trial data from ESMO GI examines correlates of response to encorafenib plus cetuximab and chemo. (Oncodaily)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care team.
CRC Research Update — June 25, 2026
Today's colorectal cancer research highlights
CRC Research Update — June 10, 2026
Today's colorectal cancer research highlights
BRAF V600E screening identifies candidates for perioperative therapy
Skip to content
The CRC Digest
BRAF V600E screening identifies candidates for perioperative therapy
Multicenter screening evaluated preoperative BRAF V600E mutation detection in patients with resectable colorectal oligometastases, enabling recruitment to a trial of the BEACON triplet regimen. (Int J Clin Oncol)
This content is informational only and does not
CRC Research Update — June 06, 2026
Today's colorectal cancer research highlights